BioSpace News Archive

Drug Development

Enterome’s EB8018, A First-in-Class Drug Candidate Targeting Crohn’s Disease, Successfully Completes Phase I Study in Healthy Volunteers

EB8018 was found to be well tolerated in healthy volunteers across a wide range of doses tested

October 30, 2017

·

4 min read

Business

Kare Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017

Kare has extensive global pharmaceutical experience and a strong track record in corporate turnarounds, as well as in driving growth and leading international expansion.

October 30, 2017

·

8 min read

Business

Medpace Holdings, Inc. Reports Third Quarter 2017 Results

Net service revenue for the three months ended September 30, 2017 was $98.7 million, an increase of 4.1%, compared to $94.8 million for the comparable prior-year period.

October 30, 2017

·

24 min read

Pharnext’s PLEODRUG PXT3003 to Be Featured at the Upcoming Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit

Pharnext will present, in a poster and during an oral session, an update on its ongoing pivotal Phase 3 clinical trial evaluating its lead PLEODRUG PXT3003.

October 30, 2017

·

3 min read

Business

Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results.

October 30, 2017

·

1 min read

Business

Incyte Names New Member to Its Board of Directors

Incyte Corporation today announced the appointment of Jacqualyn Fouse, Ph.D., as a new member of the Board of Directors, effective November 14, 2017.

October 30, 2017

·

2 min read

Business

InVivo Therapeutics Provides Business Update and Reports 2017 Third Quarter Financial Results

Of the 19 patients implanted in The INSPIRE Study to date, 16 patients are in follow-up, 14 of whom have reached the six-month primary endpoint visit.

October 30, 2017

·

9 min read

Business

Impax Announces Consent Solicitation

Impax announced today the commencement of a consent solicitation with respect to its 2.00% Convertible Senior Notes due 2022.

October 30, 2017

·

8 min read

Business

Hemogenyx Pharma Release: LakePharma Appointed As Service Provider for Lead Drug Development

The relationship between Hemogenyx Pharmaceuticals and LakePharma is designed to have a seamless product development process, from discovery to biomanufacturing

October 30, 2017

·

5 min read

Deals

Quest Diagnostics Acquires California Laboratory Associates

Quest will add several CLA patient service centers to its network in the San Fernando Valley and neighboring communities.

October 30, 2017

·

2 min read